Immunohistochemical analysis of the immune checkpoint molecule Galectin-9 in meningiomas
Abstract
Purpose: Most meningiomas can be treated by surgical resection. However, depending on the location of the lesion, incomplete resection or high-grade meningiomas may have a poor prognosis. The new methods such as immunotherapy may improve our options for effective, patient-specific treatment of meningiomas. We aim to contribute to the development of new personalized treatment strategies by investigating the status of Gal-9 in meningiomas.
Materials and Methods: Four hundred two cases diagnosed in our laboratory between 2007 and 2020 were used for the study. New blocks of multiple tissues were prepared for immunohistochemistry using the tissue microarray method. Immunohistochemical staining of Gal-9 antibody was evaluated using the H-score method.
Results: Of the 402 cases studied, 289 were female and 113 were male. Two hundred and seventy-one (67.4%) cases were WHO grade 1; 121 (30.1%) were grade 2 and 10 (2.5%) were grade 3. A high H-score was observed in grade 1 and 2 tumors (H-score: 93.38 and 93.91) and a low H-score in grade 3 tumors (H-score: 59.40). There was no significant correlation between brain invasion and Gal-9 expression. No significant correlation was found between Gal-9 expression and minor criteria used in tumor grading.
Conclusion: A statistically significant difference was found between Gal-9 H-score and tumor grade. Gal-9 had a lower H-score in high-grade meningiomas and its expression level decreased. Therefore, Gal-9 with different expression levels can be used as a prognostic and predictive biomarker as well as an important molecule for treatment.
Keywords
Meningioma, Galectin-9, immunotherapy, immune checkpoint molecules, H score
Supporting Institution
The Scientific And Technological Research Council Of Turkey (TUBİTAK)
Project Number
220S403
Ethical Statement
There are no conflicts of interest in connection with this paper, and the material described is not under publication or consideration for publication elsewhere.
References
- Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17:iv1-62.
- Al-Rashed M, Foshay K, Abedalthagafi M. Recent advances in meningioma immunogenetics. Front Oncol. 2020;9:1472.
- Moar P, Tandon R. Gal-9 as a biomarker of disease severity. Cell Immunol. 2021;361:104287.
- Torp SH, Solheim O, Skjulsvik AJ. The WHO 2021 Classification of central nervous system tumours: a practical update on what neurosurgeons need to know-a minireview. Acta Neurochir (Wien). 2022;164:2453-64.
- Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44:E3.
- Shahbandi A, Shah DS, Hadley CC, Patel AJ. The role of pharmacotherapy in treatment of meningioma: a systematic review. Cancers. 2023;12;15:483.
- Foy SP. Mandl SJ. Dela Cruz T et al. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunol Immunother. 2016;65:537‐49.
- Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T et al. Check point blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577‐81.
- Yang R, Sun L, Li CF, Wang YH, Xia W, Liu B et al. Development and characterization of anti-gal-9 antibodies that protect T cells from galectin-9-induced cell death. J Biol Chem. 2022;298:101821.
- Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al. The Tim-3 ligand gal-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245-52.
